Skip to main content
Erschienen in: Immunologic Research 2-3/2013

01.07.2013 | Etio Pathogenesis of Autoimmunity

Adverse events following immunization with vaccines containing adjuvants

verfasst von: S. Cerpa-Cruz, P. Paredes-Casillas, E. Landeros Navarro, A. G. Bernard-Medina, G. Martínez-Bonilla, S. Gutiérrez-Ureña

Erschienen in: Immunologic Research | Ausgabe 2-3/2013

Einloggen, um Zugang zu erhalten

Abstract

A traditional infectious disease vaccine is a preparation of live attenuated, inactivated or killed pathogen that stimulates immunity. Vaccine immunologic adjuvants are compounds incorporated into vaccines to enhance immunogenicity. Adjuvants have recently been implicated in the new syndrome named ASIA autoimmune/inflammatory syndrome induced by adjuvants. The objective describes the frequencies of post-vaccination clinical syndrome induced by adjuvants. We performed a cross-sectional study; adverse event following immunization was defined as any untoward medical occurrence that follows immunization 54 days prior to the event. Data on vaccinations and other risk factors were obtained from daily epidemiologic surveillance. Descriptive statistics were done using means and standard deviation, and odds ratio adjusted for potential confounding variables was calculated with SPSS 17 software. Forty-three out of 120 patients with moderate or severe manifestations following immunization were hospitalized from 2008 to 2011. All patients fulfilled at least 2 major and 1 minor criteria suggested by Shoenfeld and Agmon–Levin for ASIA diagnosis. The most frequent clinical findings were pyrexia 68 %, arthralgias 47 %, cutaneous disorders 33 %, muscle weakness 16 % and myalgias 14 %. Three patients had diagnosis of Guillain–Barre syndrome, one patient had Adult-Still’s disease 3 days after vaccination. A total of 76 % of the events occurred in the first 3 days post-vaccination. Two patients with previous autoimmune disease showed severe adverse reactions with the reactivation of their illness. Minor local reactions were present in 49 % of patients. Vaccines containing adjuvants may be associated with an increased risk of autoimmune/inflammatory adverse events following immunization.
Literatur
1.
2.
Zurück zum Zitat Kwissa M, Kasturi SP, Pulendran B. The science of adjuvants. Expert Rev Vaccines. 2007;6(5):673–84.PubMedCrossRef Kwissa M, Kasturi SP, Pulendran B. The science of adjuvants. Expert Rev Vaccines. 2007;6(5):673–84.PubMedCrossRef
3.
Zurück zum Zitat Cruz-Tapias P, et al. Infections and vaccines in the etiology of antiphospholipid syndrome. Curr Opin Rheumatol. 2012;24(4):389–93.PubMedCrossRef Cruz-Tapias P, et al. Infections and vaccines in the etiology of antiphospholipid syndrome. Curr Opin Rheumatol. 2012;24(4):389–93.PubMedCrossRef
4.
Zurück zum Zitat de Veer M, Meeusen E. New developments in vaccine research—unveiling the secret of vaccine adjuvants. Discov Med. 2011;12(64):195–204.PubMed de Veer M, Meeusen E. New developments in vaccine research—unveiling the secret of vaccine adjuvants. Discov Med. 2011;12(64):195–204.PubMed
5.
6.
Zurück zum Zitat Schijns VE, Lavelle EC. Trends in vaccine adjuvants. Expert Rev Vaccines. 2011;10(4):539–50.PubMedCrossRef Schijns VE, Lavelle EC. Trends in vaccine adjuvants. Expert Rev Vaccines. 2011;10(4):539–50.PubMedCrossRef
7.
Zurück zum Zitat Shoenfeld Y, Agmon-Levin N. ‘ASIA’ - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36(1):4–8.PubMedCrossRef Shoenfeld Y, Agmon-Levin N. ‘ASIA’ - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36(1):4–8.PubMedCrossRef
8.
Zurück zum Zitat WHO. Surveillance of adverse events following immunization. Field guide for managers of immunization programmes. Geneva. 1997. WHO. Surveillance of adverse events following immunization. Field guide for managers of immunization programmes. Geneva. 1997.
9.
Zurück zum Zitat WHO. Supplementary information on vaccine safety. Part 2. Background rates of adverse events following immunization. Geneva. 2000. WHO. Supplementary information on vaccine safety. Part 2. Background rates of adverse events following immunization. Geneva. 2000.
10.
Zurück zum Zitat Vitoriano-Souza J, et al. Cell recruitment and cytokines in skin mice sensitized with the vaccine adjuvants: saponin, incomplete Freund’s adjuvant, and monophosphoryl lipid A. PLoS One. 2012;7(7):e40745.PubMedCrossRef Vitoriano-Souza J, et al. Cell recruitment and cytokines in skin mice sensitized with the vaccine adjuvants: saponin, incomplete Freund’s adjuvant, and monophosphoryl lipid A. PLoS One. 2012;7(7):e40745.PubMedCrossRef
11.
Zurück zum Zitat Levy O, Goriely S, Kollmann TR. Immune response to vaccine adjuvants during the first year of life. Vaccine. 2012. Levy O, Goriely S, Kollmann TR. Immune response to vaccine adjuvants during the first year of life. Vaccine. 2012.
12.
Zurück zum Zitat Katzav A, Kivity S, Blank M, Shoenfeld Y, Chapman J. Adjuvant immunization induces high levels of pathogenic antiphospholipid antibodies in genetically prone mice: another facet of the ASIA syndrome. Lupus. 2012;21:210–6.PubMedCrossRef Katzav A, Kivity S, Blank M, Shoenfeld Y, Chapman J. Adjuvant immunization induces high levels of pathogenic antiphospholipid antibodies in genetically prone mice: another facet of the ASIA syndrome. Lupus. 2012;21:210–6.PubMedCrossRef
13.
14.
Zurück zum Zitat Zafrir Y, et al. Autoimmunity following hepatitis B vaccine as part of the spectrum of ‘Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants’ (ASIA): analysis of 93 cases. Lupus. 2012;21(2):146–52.PubMedCrossRef Zafrir Y, et al. Autoimmunity following hepatitis B vaccine as part of the spectrum of ‘Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants’ (ASIA): analysis of 93 cases. Lupus. 2012;21(2):146–52.PubMedCrossRef
15.
Zurück zum Zitat Perdan-Pirkmajer K, et al. Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease. Lupus. 2012;21(2):175–83.PubMedCrossRef Perdan-Pirkmajer K, et al. Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease. Lupus. 2012;21(2):175–83.PubMedCrossRef
16.
Zurück zum Zitat Ray P, et al. Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15–59 years of age. Vaccine. 2011;29(38):6592–7.PubMedCrossRef Ray P, et al. Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15–59 years of age. Vaccine. 2011;29(38):6592–7.PubMedCrossRef
17.
Zurück zum Zitat Tomljenovic L, Shaw CA. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations. Lupus. 2012;21(2):223–30.PubMedCrossRef Tomljenovic L, Shaw CA. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations. Lupus. 2012;21(2):223–30.PubMedCrossRef
18.
Zurück zum Zitat Lukiw WJ, Percy ME, Kruck TP. Nanomolar aluminum induces pro-inflammatory and pro-apoptotic gene expression in human brain cells in primary culture. J Inorg Biochem. 2005;99(9):1895–8.PubMedCrossRef Lukiw WJ, Percy ME, Kruck TP. Nanomolar aluminum induces pro-inflammatory and pro-apoptotic gene expression in human brain cells in primary culture. J Inorg Biochem. 2005;99(9):1895–8.PubMedCrossRef
19.
Zurück zum Zitat Eisenbarth SC, et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008;453(7198):1122–6.PubMedCrossRef Eisenbarth SC, et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008;453(7198):1122–6.PubMedCrossRef
20.
Zurück zum Zitat Gherardi RK, Authier FJ. Macrophagic myofasciitis: characterization and pathophysiology. Lupus. 2012;21(2):184–9.PubMedCrossRef Gherardi RK, Authier FJ. Macrophagic myofasciitis: characterization and pathophysiology. Lupus. 2012;21(2):184–9.PubMedCrossRef
21.
Zurück zum Zitat Agmon-Levin N, Hughes GR, Shoenfeld Y. The spectrum of ASIA: ‘Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants’. Lupus. 2012;21(2):118–20.PubMedCrossRef Agmon-Levin N, Hughes GR, Shoenfeld Y. The spectrum of ASIA: ‘Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants’. Lupus. 2012;21(2):118–20.PubMedCrossRef
22.
Zurück zum Zitat Exley C, Siesjo P, Eriksson H. The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol. 2010;31(3):103–9.PubMedCrossRef Exley C, Siesjo P, Eriksson H. The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol. 2010;31(3):103–9.PubMedCrossRef
23.
Zurück zum Zitat Whitehouse M. Oily adjuvants and autoimmunity: now time for reconsideration? Lupus. 2012;21(2):217–22.PubMedCrossRef Whitehouse M. Oily adjuvants and autoimmunity: now time for reconsideration? Lupus. 2012;21(2):217–22.PubMedCrossRef
24.
25.
Zurück zum Zitat Barile JP, et al. Thimerosal exposure in early life and neuropsychological outcomes 7–10 years later. J Pediatr Psychol. 2012;37(1):106–18.PubMedCrossRef Barile JP, et al. Thimerosal exposure in early life and neuropsychological outcomes 7–10 years later. J Pediatr Psychol. 2012;37(1):106–18.PubMedCrossRef
26.
Zurück zum Zitat Madi A. Being on the track of thimerosal. Review. Acta Microbiol Immunol Hung. 2005;52(1):95–103.PubMedCrossRef Madi A. Being on the track of thimerosal. Review. Acta Microbiol Immunol Hung. 2005;52(1):95–103.PubMedCrossRef
27.
Zurück zum Zitat Barregard L, et al. Toxicokinetics of mercury after long-term repeated exposure to thimerosal-containing vaccine. Toxicol Sci. 2011;120(2):499–506.PubMedCrossRef Barregard L, et al. Toxicokinetics of mercury after long-term repeated exposure to thimerosal-containing vaccine. Toxicol Sci. 2011;120(2):499–506.PubMedCrossRef
28.
Zurück zum Zitat Soriano A, et al. Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature. Lupus. 2012;21(2):153–7.PubMedCrossRef Soriano A, et al. Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature. Lupus. 2012;21(2):153–7.PubMedCrossRef
Metadaten
Titel
Adverse events following immunization with vaccines containing adjuvants
verfasst von
S. Cerpa-Cruz
P. Paredes-Casillas
E. Landeros Navarro
A. G. Bernard-Medina
G. Martínez-Bonilla
S. Gutiérrez-Ureña
Publikationsdatum
01.07.2013
Verlag
Springer-Verlag
Erschienen in
Immunologic Research / Ausgabe 2-3/2013
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-013-8400-4

Weitere Artikel der Ausgabe 2-3/2013

Immunologic Research 2-3/2013 Zur Ausgabe

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.